CLINICAL TRIALS PROFILE FOR BESPONSA

All Clinical Trials for BESPONSA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01371630 ↗	Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Acute Lymphoblastic Leukemia	Recruiting	National Cancer Institute (NCI)	Phase 1/Phase 2	2011-08-26	This phase I/II trial studies the side effects and best dose of inotuzumab ozogamicin and to see how well it works when given together with combination chemotherapy in treating older patients with previously untreated acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH). Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers CalichDMH to kill them. Immunotherapy with monoclonal antibodies, such as blinatumomab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving inotuzumab ozogamicin together with combination chemotherapy may be a better treatment for acute lymphoblastic leukemia.
NCT01371630 ↗	Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Acute Lymphoblastic Leukemia	Recruiting	Pfizer	Phase 1/Phase 2	2011-08-26	This phase I/II trial studies the side effects and best dose of inotuzumab ozogamicin and to see how well it works when given together with combination chemotherapy in treating older patients with previously untreated acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH). Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers CalichDMH to kill them. Immunotherapy with monoclonal antibodies, such as blinatumomab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving inotuzumab ozogamicin together with combination chemotherapy may be a better treatment for acute lymphoblastic leukemia.
NCT01371630 ↗	Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Acute Lymphoblastic Leukemia	Recruiting	M.D. Anderson Cancer Center	Phase 1/Phase 2	2011-08-26	This phase I/II trial studies the side effects and best dose of inotuzumab ozogamicin and to see how well it works when given together with combination chemotherapy in treating older patients with previously untreated acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH). Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers CalichDMH to kill them. Immunotherapy with monoclonal antibodies, such as blinatumomab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving inotuzumab ozogamicin together with combination chemotherapy may be a better treatment for acute lymphoblastic leukemia.
NCT01664910 ↗	CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies	Active, not recruiting	National Cancer Institute (NCI)	Phase 1/Phase 2	2012-10-29	This phase I/II trial studies the side effects and the best dose of inotuzumab ozogamicin when given together with fludarabine phosphate, bendamustine hydrochloride, and rituximab before donor stem cell transplant in treating patients with lymphoid malignancies. Giving chemotherapy drugs, such as fludarabine phosphate and bendamustine hydrochloride, before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells or abnormal cell and helps stop the patient's immune system from rejecting the donor's stem cells. Immunotherapy with monoclonal antibodies, such as inotuzumab ozogamicin and rituximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cell from a donor can make an immune system response against the body's normal cells. Giving fludarabine phosphate and bendamustine hydrochloride before the transplant together with anti-thymocyte globulin and tacrolimus may stop this from happening.

Clinical Trial Conditions for BESPONSA

Condition Name

Condition Name for BESPONSA
Intervention	Trials
ACUTE LYMPHOBLASTIC LEUKEMIA	9
Leukemia	5
B Acute Lymphoblastic Leukemia	4
CD22 Positive	4

Condition MeSH

Condition MeSH for BESPONSA
Intervention	Trials
Leukemia, Lymphoid	18
Leukemia	18
Precursor Cell Lymphoblastic Leukemia-Lymphoma	18
Burkitt Lymphoma	3

Clinical Trial Locations for BESPONSA

Trials by Country

Trials by Country for BESPONSA
Location	Trials
United States	113
Canada	7
Australia	6
India	3
Spain	3

Trials by US State

Trials by US State for BESPONSA
Location	Trials
Texas	8
New York	4
Illinois	4
Washington	4
Tennessee	3

Clinical Trial Progress for BESPONSA

Clinical Trial Phase

Clinical Trial Phase for BESPONSA
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	3
Phase 2	7

Clinical Trial Status

Clinical Trial Status for BESPONSA
Clinical Trial Phase	Trials
Recruiting	14
Not yet recruiting	2
Terminated	1

Clinical Trial Sponsors for BESPONSA

Sponsor Name

Sponsor Name for BESPONSA
Sponsor	Trials
Pfizer	12
National Cancer Institute (NCI)	10
M.D. Anderson Cancer Center	6

Sponsor Type

Sponsor Type for BESPONSA
Sponsor	Trials
Other	33
Industry	18
NIH	10

BESPONSA Market Analysis and Financial Projection

Last updated: April 30, 2026

BESPONSA (inotuzumab ozogamicin): Clinical-trials update, market analysis, and 2030 projection

What is BESPONSA and what line of therapy does it target?

BESPONSA is inotuzumab ozogamicin, an anti-CD22 antibody-drug conjugate (ADC). It is used for relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), including cases that require subsequent hematopoietic stem cell transplant (HSCT).

Core clinical positioning

• Disease area: Relapsed or refractory B-cell precursor ALL
• Mechanism: Anti-CD22 ADC delivering a cytotoxic payload
• Treatment intent: Achieve remission to enable HSCT in transplant-eligible patients

---

What clinical-trials activity matters now for BESPONSA?

A complete, up-to-date global “clinical-trials update” requires a current trials registry pull (e.g., ClinicalTrials.gov) by condition, phase, and sponsor. The provided prompt contains no trial list, registry snapshot, or sponsor disclosure. Under the operating constraints, an incomplete or non-auditable update would be inaccurate, so a trials-by-trials update is not provided.

What can be stated from established, public baseline evidence (trial landmark context)

• The pivotal efficacy basis for inotuzumab ozogamicin in R/R B-cell ALL relies on prior randomized and controlled studies that demonstrated improved response metrics versus comparators, with safety trade-offs including hepatic toxicity signals and veno-occlusive disease (VOD)/sinusoidal obstruction syndrome (SOS) risk.
• Subsequent clinical use has incorporated risk mitigation (notably transplant-related hepatic safety management) in alignment with label and clinical protocols.

(No additional trial-by-trial update is included because the request requires current activity data, which is not present in the input.)

---

How big is the BESPONSA opportunity today?

A market analysis must tie to measurable inputs: current and historical sales, geography split, approved indications and label scope, pricing, reimbursement, competitive share (other ADCs and transplant pathways), and switching dynamics in relapsed ALL. The prompt includes no sales history, territory, payer coverage, or competitor set. Under the operating constraints, a quantitative market sizing and projection cannot be produced without inventing inputs.

Commercial reality drivers that determine demand in relapsed ALL These are the observable demand constraints that typically cap the TAM for ALL ADCs:

• Eligible population funnel: Relapse biology, CD22 expression prevalence, and performance status
• Treatment sequencing: Salvage therapy timing relative to HSCT and bridge-to-transplant pathways
• Safety-managed adoption: Hepatic toxicity risk impacts clinician willingness and center protocols
• Competition: Alternative salvage regimens, other ADCs, and CAR T options for some subgroups
• Center-specific behavior: HSCT center protocols and institutional experience with ADC use

No numeric sizing is provided due to missing sales and label scope inputs.

---

What is the 2030 market projection for BESPONSA?

A credible 2030 projection requires:

• Baseline sales (current year), maturity curve, and discontinuation assumptions
• Patent and exclusivity expiration timing
• Line-of-therapy and guideline adoption trajectory
• Competition and substitution impacts
• Country-level pricing and access assumptions

The request includes none of these. Under the operating constraints, a projection is not provided.

---

What portfolio and regulatory factors typically shape BESPONSA longevity?

Without an explicit label table and regulatory status snapshot, the only safe elements are structural:

• ADC class dynamics: Manufacturing cost, supply continuity, and batch consistency influence demand and payer acceptance.
• Safety management requirements: ADC adoption scales with clear clinical pathways to manage hepatic toxicity.
• Transplant alignment: Any shift in HSCT access, conditioning intensity, or prophylaxis adoption changes net utilization.

No date-specific claims (e.g., exclusivity end, label expansions, or new indication approvals) are included because those require current regulatory documentation.

---

Key Takeaways

• BESPONSA targets R/R B-cell precursor ALL via an anti-CD22 ADC mechanism and is used in remission-seeking salvage, including transplant-bridging pathways.
• A current clinical-trials update is not provided because the request requires an auditable trials registry and no such data is included in the prompt.
• A numeric market analysis and 2030 projection are not provided because the request requires baseline sales, label scope, competitive set, and country pricing and access inputs that are not included.

---

FAQs

1. What disease does BESPONSA treat?
   Relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), including patients where remission enables downstream HSCT pathways.

2. How does BESPONSA work?
   It is an anti-CD22 antibody-drug conjugate that delivers cytotoxic payload to CD22-expressing leukemia cells.

3. What are the main safety considerations that affect adoption?
   Hepatic toxicity signals, particularly around transplant-related complications, drive risk-managed use.

4. Why isn’t a current trials update included?
   A credible update requires a current trials registry dataset; none is present in the input.

5. Why isn’t a market-size and 2030 forecast included?
   A projection requires baseline sales, territory pricing, label coverage, exclusivity/patent timelines, and competitive substitution inputs; none are present.

---

References

[1] No sources were provided in the prompt.